Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IRX2 divergent transcript (IRX2-DT) is a human long non-coding RNA gene located on chromosome 5 near the IRX2 protein-coding gene. It is classified as a divergent transcript, meaning it is found within 300–500 nucleotides of a protein coding gene and transcribed in the opposite direction. While some basic molecular function annotation (protein binding) exists, its biological role, disease association, and relevance as a therapeutic target are not established. The numerous aliases stem from its genomic neighbourhood (e.g., IRX2 neighbor, C5orf38) and historical annotation, but the gene is presently defined as non-coding and does not encode an active receptor, enzyme, or protein. No therapeutics, biomarkers, or clinical safety issues are associated with IRX2-DT. IRX2-DT is a long non-coding RNA and is not considered a receptor or canonical therapeutic target. The current nomenclature includes repeats and ambiguous or incorrect synonyms; only the established lncRNA name applies. There is no evidence for drug interaction or disease role in curated sources.
None — no mechanisms are described as IRX2-DT is not targeted by drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IRX2 divergent transcript (IRX2-DT).